Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.59 |
| ▸ | ESR1 | P03372 | 10/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443017 | 1.00 | TAAR1 (0.59) | TAAR1SLC6A2ESR1ESR2LMNA | |
| SCHEMBL13165991 | 1.00 | TAAR1 (0.59) | TAAR1SLC6A2ESR1ESR2LMNA | |
| SCHEMBL8687796 | 0.94 | TAAR1 (0.53) | TAAR1SLC6A2ESR1ESR2LMNA | |
| SCHEMBL1120020 | 0.94 | TAAR1 (0.53) | TAAR1SLC6A2ESR1ESR2LMNA | |
| SCHEMBL27776965 | 0.90 | TAAR1 (0.53) | TAAR1SLC6A2ESR1ESR2LMNA | |
| SCHEMBL7084861 | 0.90 | TAAR1 (0.53) | TAAR1SLC6A2ESR1ESR2LMNA | |
| SCHEMBL3264679 | 0.88 | TAAR1 (0.67) | TAAR1SLC6A2ESR1ESR2CYP1A2 | |
| SCHEMBL18568218 | 0.87 | ESR1 (0.55) | TAAR1SLC6A2ESR1ESR2LMNA | |
| SCHEMBL1052306 | 0.83 | ESR1 (0.61) | TAAR1SLC6A2ESR1ESR2LMNA | |
| SCHEMBL14495615 | 0.83 | ESR1 (0.61) | TAAR1SLC6A2ESR1ESR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160307869-A1 | LASER DIE BACKSIDE FILM REMOVAL FOR INTEGRATED CIRCUIT (IC) PACKAGING | INTEL CORP (US) | 2016-10-20 | — | — | US | disclosed |
| US-9412702-B2 | Laser die backside film removal for integrated circuit (IC) packaging | INTEL CORPORATION (US) | 2016-08-09 | — | — | US | disclosed |
| US-20140264951-A1 | LASER DIE BACKSIDE FILM REMOVAL FOR INTEGRATED CIRCUIT (IC) PACKAGING | INTEL CORPORATION | 2014-09-18 | — | — | US | disclosed |
| US-7803804-B2 | Substituted pyrazines for use in the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2010-09-28 | — | — | US | disclosed |
| US-7803804-B2 | Substituted pyrazines for use in the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2010-09-28 | — | — | US | disclosed |
| US-20080312217-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| US-20080312217-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| WO-2007071396-A2 | PYRAZINOYLGUANIDINE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| EP-1214306-A1 | LIQUID CRYSTAL COMPOUNDS | Qinetiq Limited (GB) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001021606-A1 | LIQUID CRYSTAL COMPOUNDS | QINETIQ LIMITED (GB) | 2001-03-29 | — | — | WO | disclosed |
| US-5389290-A | Ferroelectric liquid crystalline materials | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-02-14 | — | — | US | disclosed |
| EP-0255236-B1 | Fluorine-containing chiral smectic liquid crystals | MINNESOTA MINING & MFG (US) | 1994-05-04 | — | — | EP | disclosed |
| US-5254747-A | Fluorine-containing chiral smectic liquid crystals | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-10-19 | — | — | US | disclosed |
| US-5089168-A | Stable ferroelectric liquid crystals | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1992-02-18 | — | — | US | disclosed |
| EP-0220297-B1 | NITROGEN-CONTAINING HETEROCYCLES | MERCK PATENT GmbH (DE) | 1991-12-11 | — | — | EP | disclosed |
| US-4886619-A | TILTED OR LATENT TILTED MESOPHASES; BLENDS; FERROELECTRIC DEVICE | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1989-12-12 | — | — | US | disclosed |
| US-4834904-A | FERROELECTRIC LIQUID CRYSTALS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1989-05-30 | — | — | US | disclosed |
| EP-0255236-A2 | Fluorine-containing chiral smectic liquid crystals | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1988-02-03 | — | — | EP | disclosed |
| EP-0220297-A1 | NITROGEN-CONTAINING HETEROCYCLES. | MERCK PATENT GMBH (DE) | 1987-05-06 | — | — | EP | disclosed |
| WO-1986006373-A1 | NITROGEN-CONTAINING HETEROCYCLES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1986-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312217-A1 | Organic Compounds | TRPA1, TRPV1, CHRM1 | TAAR1 301/4885SLC6A2 694/4885ESR1 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.